386 related articles for article (PubMed ID: 27425170)
1. Omalizumab use during pregnancy for CIU: a tertiary care experience.
Cuervo-Pardo L; Barcena-Blanch M; Radojicic C
Eur Ann Allergy Clin Immunol; 2016 Jul; 48(4):145-6. PubMed ID: 27425170
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of omalizumab in severe chronic spontaneous urticaria: Real life data from a Greek tertiary center.
Kyriakou A; Trigoni A; Sotiriadis D; Patsatsi A
Dermatol Ther; 2018 Nov; 31(6):e12739. PubMed ID: 30194796
[No Abstract] [Full Text] [Related]
3. Efficacy of Omalizumab Treatment with Concomitant Antihistamines as Needed for Moderate, Refractory Chronic Spontaneous Urticaria.
Nettis E; Cegolon L; Macchia L; Zaza I; Calogiuri G; Di Leo E
Acta Derm Venereol; 2018 Apr; 98(4):446-448. PubMed ID: 29362811
[No Abstract] [Full Text] [Related]
4. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence.
Bernstein JA; Kavati A; Tharp MD; Ortiz B; MacDonald K; Denhaerynck K; Abraham I
Expert Opin Biol Ther; 2018 Apr; 18(4):425-448. PubMed ID: 29431518
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab as Third-Line Therapy for Urticaria During Pregnancy.
Ensina LF; Cusato-Ensina AP; Camelo-Nunes IC; Solé D
J Investig Allergol Clin Immunol; 2017; 27(5):326-327. PubMed ID: 29057743
[No Abstract] [Full Text] [Related]
6. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
7. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL
J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177
[TBL] [Abstract][Full Text] [Related]
8. Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States.
Ke X; Kavati A; Wertz D; Huang Q; Wang L; Willey VJ; Stephenson JJ; Ortiz B; Paknis B; Bernstein JA; Beck LA
J Manag Care Spec Pharm; 2018 Jul; 24(7):598-606. PubMed ID: 29952712
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab-induced triphasic anaphylaxis in a patient with chronic spontaneous urticaria.
Gönül M; Özenergün Bittacı A; Ergin C
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e135-e136. PubMed ID: 26446412
[No Abstract] [Full Text] [Related]
10. Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study.
Casale TB; Win PH; Bernstein JA; Rosén K; Holden M; Iqbal A; Trzaskoma BL; Yang M; Antonova EN; Murphy T; Scarupa MD; Sofen H; Kaplan A
J Am Acad Dermatol; 2018 Apr; 78(4):793-795. PubMed ID: 29037993
[No Abstract] [Full Text] [Related]
11. Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.
Tharp MD; Bernstein JA; Kavati A; Ortiz B; MacDonald K; Denhaerynck K; Abraham I; Lee CS
JAMA Dermatol; 2019 Jan; 155(1):29-38. PubMed ID: 30427977
[TBL] [Abstract][Full Text] [Related]
12. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
Giménez-Arnau AM
Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases.
González-Medina M; Curto-Barredo L; Labrador-Horrillo M; Giménez-Arnau A
J Eur Acad Dermatol Venereol; 2017 May; 31(5):e245-e246. PubMed ID: 27868240
[No Abstract] [Full Text] [Related]
14. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
Saini S; Rosen KE; Hsieh HJ; Wong DA; Conner E; Kaplan A; Spector S; Maurer M
J Allergy Clin Immunol; 2011 Sep; 128(3):567-73.e1. PubMed ID: 21762974
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C.
Leiva-Salinas M; Francés L; Marin-Cabanas I; Arribas Granados MP; Silvestre JF
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1027-8. PubMed ID: 24629127
[No Abstract] [Full Text] [Related]
17. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
18. Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective study.
Serarslan G; Uzun M; Doğramacı AÇ; Çelik E
Dermatol Ther; 2019 Jan; 32(1):e12752. PubMed ID: 30238582
[TBL] [Abstract][Full Text] [Related]
19. Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria.
Koski R; Kennedy KK
Ann Allergy Asthma Immunol; 2017 Nov; 119(5):397-401. PubMed ID: 29150066
[No Abstract] [Full Text] [Related]
20. Omalizumab for refractory chronic spontaneous urticaria during concurrent immunomodulatory therapy for multiple sclerosis.
Syrigos N; Grapsa D; Syrigou E
Eur Ann Allergy Clin Immunol; 2017 Nov; 49(6):286-287. PubMed ID: 29249139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
